A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults

This multicenter double-blind trial randomized 66 healthy middle-aged and older adults to 300 mg/day NMN or placebo for 60 days. The report describes increases in serum NAD+/NADH and differences in some secondary functional and questionnaire outcomes.

A notable analytical issue is that randomization produced 31 active and 35 placebo participants; after unblinding, 31 placebo participants were selected so that 31 participants per group were analyzed. That post-randomization selection lowers confidence in effect estimates.

The study reported no major safety signal over 60 days. HOMA-IR did not show a clear treatment benefit, and several endpoints should be interpreted as exploratory.

• Serum NAD+/NADH increased over 60 days in the NMN arm relative to baseline and placebo.
• The report described greater improvement in six-minute walk distance and SF-36 scores in the NMN arm.
• HOMA-IR did not show a clear statistically significant treatment effect.
• Two mild dyslipidemia adverse events were reported, one in each group, and were judged unlikely related to study product.
• The analyzed population was reduced to 31 per arm after unblinding because the randomized group sizes were imbalanced.

• Short 60-day intervention.
• The sole author was an employee of the company associated with the branded NMN product.
• Post-unblinding random selection of placebo participants is an important analysis limitation.
• Multiple endpoints increase the risk of chance findings.
• The healthy 40–65-year-old population limits generalizability to disease treatment or older frail populations.